Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Fineline Cube Dec 30, 2025
Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Fineline Cube Dec 30, 2025
Company Deals

Yifan Pharmaceutical Licenses F-627 to Acrotech for US Distribution

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the establishment of a licensing agreement with...

Company Deals Digital

Nans Tech Secures Series A Funding for Brain Dysfunction Digital Therapies

Fineline Cube Dec 1, 2022

Nans Tech, a brain dysfunction digital therapy developer based in Hangzhou, reportedly raised “tens of...

Company Deals

Aclaris Therapeutics Licenses JAK Inhibitor ATI-1777 to Pediatrix for Greater China

Fineline Cube Dec 1, 2022

US-based Aclaris Therapeutics Inc. (NASDAQ: ACRS) and Shanghai firm Pediatrix Therapeutics Inc. entered into a...

Policy / Regulatory

China’s NMPA Issues New GSP Appendix for Drug Retailing Quality Management

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released “Good Supply Practice (GSP) Appendix 6: Quality...

Company Drug

ImmuneOnco Initiates Phase II Clinical Study for CD47 Antibody IMM01

Fineline Cube Dec 1, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the initiation of a Phase II clinical study...

Policy / Regulatory

China’s NMPA Seeks Feedback on Drug Quality Management Provisions

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Provisions on the...

Company Deals

Luye Pharma’s Shandong Boan Bio Files for Hong Kong IPO

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has filed...

Company Deals

Luca Healthcare Partners with Cambridge Cognition to Launch Cognitive Tools in China

Fineline Cube Dec 1, 2022

China-based digital health solutions provider Luca Healthcare has announced a strategic partnership and license agreement...

Company Drug

Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...

Company Medical Device

Assure Tech Wins Japanese PDMA Approval for Pen-Type COVID-19 Antigen Test

Fineline Cube Dec 1, 2022

China-based Assure Tech (Hangzhou) Co., Ltd (SHA: 688075) has announced receiving marketing approval from Japan’s...

Company Drug

Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials

Fineline Cube Dec 1, 2022

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...

Company Medical Device

Lepu Medical Wins NMPA Approval for Disposable Pressure Microcatheter

Fineline Cube Dec 1, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Policy / Regulatory

China’s NMPA Shifts to Electronic Drug Filings from January 2023

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a notification indicating the initiation of electronic...

Company Medical Device

Hainan Hospital Launches IBI’s Smartbone ORTHO for Bone Repair

Fineline Cube Dec 1, 2022

The clinical application of Smartbone ORTHO, a polyester collagen bone repair material introduced by Hainan...

Company Drug

CSL Vifor and Fresenius Kabi Win China Approval for Ferinject

Fineline Cube Dec 1, 2022

Swiss firm CSL Vifor and Germany’s Fresenius Kabi have announced the first regulatory approval in...

Company Deals

China’s Pharma Firms Collaborate on Generic Version of Sun Pharma’s Carbamazepine

Fineline Cube Dec 1, 2022

Several China-based pharmaceutical companies, including Shanghai Zhongxi Sunve Pharmaceutical Co. Ltd, Shanghai Anbison Lab Co.,...

Company Drug

Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study

Fineline Cube Dec 1, 2022

China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...

Company Deals

Henan Celnovte Biotechnology Raises RMB 100M in New Financing Round

Fineline Cube Dec 1, 2022

China-based Henan Celnovte Biotechnology Co., Ltd, a tumor in vitro diagnostic reagents (IVDs) and instruments...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Reduces Household Transmission of COVID-19

Fineline Cube Dec 1, 2022

China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced that Clinical Infectious Diseases has published...

Company Drug

Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study

Fineline Cube Dec 1, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...

Posts pagination

1 … 529 530 531 … 602

Recent updates

  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
  • TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.